# A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer

> **NCT00539383** · PHASE1 · COMPLETED · sponsor: **Angiochem Inc** · enrollment: 56 (actual)

## Conditions studied

- Advanced Solid Tumors With and Without Brain Metastases

## Interventions

- **DRUG:** ANG1005

## Key facts

- **NCT ID:** NCT00539383
- **Lead sponsor:** Angiochem Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2014-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00539383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00539383, "A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00539383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*